Table 2.
Number of lymphadenopathy cases, demographics, and dose after which symptoms developed following taking each vaccine type as reported in the randomized control trials (RTCs) and cohort studies with control
| Type of vaccine | Type of study | Number of cases (%) | Gender | Age range | Which dose | References |
|---|---|---|---|---|---|---|
| Pfizer | RTC | 64 (0.3%) | NR | 16–91 | 1st | Polack et al. 52 |
| Pfizer | Cohort study with control | 332 (45.6%) | 315 M | 57.6–76.5 | 126 1st | Cohen et al. 53 |
| 413 F | 206 2nd | |||||
| Moderna | RTC | 3710 (23.8%) | 8062 M | 18–95 | 1581 1st | Baden et al. 54 |
| 7519 F | 2129 2nd | Chu et al. 55 | ||||
| Pfizer or Modernaa | Cohort study with control | 247 (0.8%) | 133 F | NR | 189 1st | Venkatakrishnan et al. 56 |
| 114 M | 58 2nd | |||||
| Pfizer or Modernaa | Cohort study with control | Units reported as cases/person daysb | NR | NR | 152 1st | McMurry et al. 57 |
| 1st shot: | 50 2nd | |||||
| −7 days post: 78/216 571 (0.36%) | ||||||
| −14 days post: 93/432 225 (0.22%) | ||||||
| −21 days post: 152/647 178 (0.23%) | ||||||
| 2nd shot: | ||||||
| − 7 days post: 34/118 741 (0.29%) | ||||||
| −14 days post: 33/237 349 (0.14%) | ||||||
| −21 days post: 50/355 769 (0.14%) | ||||||
| Pfizer or Moderna or Janssena | Cohort study with control | 965 (2.8%) | 131 M | NR | NR | Venkatakrishnan et al. 56 |
| 834 F |
Abbreviations: COVID‐19, coronavirus disease 2019; F, Female; M, Male; NR, not reported.
a
Numbers are not separated in the study. For the study by McMurry et al., the data were extracted from the preprint where numbers were not yet separated for Pfizer and Moderna.
b
Cases/person days: Number of lymphadenopathy cases over an estimate of the actual time‐at‐risk in days that all persons contributed to the study. The study only reported this value as it looked into ED notes at a specific time period rather than a specific cohort of people.